Interferon β in Multiple Sclerosis: A Review

R. H. Gross; F. Lublin

doi:10.1016/B978-0-12-801914-6.00016-7

Interferon β in Multiple Sclerosis: A Review

R. H. Gross, F. Lublin

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

7 Scopus citations

Abstract

Interferon beta has been used to treat multiple sclerosis (MS) longer than any other disease-modifying therapy. It modulates the immune system through decreasing antigen presentation, enhancing suppressor T cells, reducing proinflammatory cytokines, and inhibiting lymphocyte trafficking into the central nervous system. Many clinical trials and over two decades of clinical experience have established it as a modestly efficacious and very safe therapeutic option for patients with relapsing MS. The side-effect profile includes flu-like symptoms, injection site reactions, liver function abnormalities, decreased peripheral blood counts, and worsening of depression. Its immunogenic properties and patients' genetic variability are associated with response heterogeneity.

Original language	English
Title of host publication	Translational Neuroimmunology in Multiple Sclerosis
Subtitle of host publication	From Disease Mechanisms to Clinical Applications
Publisher	Elsevier Inc.
Pages	191-201
Number of pages	11
ISBN (Electronic)	9780128020074
ISBN (Print)	9780128019146
DOIs	https://doi.org/10.1016/B978-0-12-801914-6.00016-7
State	Published - 3 Aug 2016

Keywords

Disease-modifying therapy
IFN
Interferon beta
Multiple sclerosis

Access to Document

10.1016/B978-0-12-801914-6.00016-7

Cite this

@inbook{d72c7941ecb443088fb14d2f2dddafc1,

title = "Interferon β in Multiple Sclerosis: A Review",

abstract = "Interferon beta has been used to treat multiple sclerosis (MS) longer than any other disease-modifying therapy. It modulates the immune system through decreasing antigen presentation, enhancing suppressor T cells, reducing proinflammatory cytokines, and inhibiting lymphocyte trafficking into the central nervous system. Many clinical trials and over two decades of clinical experience have established it as a modestly efficacious and very safe therapeutic option for patients with relapsing MS. The side-effect profile includes flu-like symptoms, injection site reactions, liver function abnormalities, decreased peripheral blood counts, and worsening of depression. Its immunogenic properties and patients' genetic variability are associated with response heterogeneity.",

keywords = "Disease-modifying therapy, IFN, Interferon beta, Multiple sclerosis",

author = "Gross, \{R. H.\} and F. Lublin",

year = "2016",

month = aug,

day = "3",

doi = "10.1016/B978-0-12-801914-6.00016-7",

language = "English",

isbn = "9780128019146",

pages = "191--201",

booktitle = "Translational Neuroimmunology in Multiple Sclerosis",

publisher = "Elsevier Inc.",

address = "United States",

}

TY - CHAP

T1 - Interferon β in Multiple Sclerosis

T2 - A Review

AU - Gross, R. H.

AU - Lublin, F.

PY - 2016/8/3

Y1 - 2016/8/3

N2 - Interferon beta has been used to treat multiple sclerosis (MS) longer than any other disease-modifying therapy. It modulates the immune system through decreasing antigen presentation, enhancing suppressor T cells, reducing proinflammatory cytokines, and inhibiting lymphocyte trafficking into the central nervous system. Many clinical trials and over two decades of clinical experience have established it as a modestly efficacious and very safe therapeutic option for patients with relapsing MS. The side-effect profile includes flu-like symptoms, injection site reactions, liver function abnormalities, decreased peripheral blood counts, and worsening of depression. Its immunogenic properties and patients' genetic variability are associated with response heterogeneity.

AB - Interferon beta has been used to treat multiple sclerosis (MS) longer than any other disease-modifying therapy. It modulates the immune system through decreasing antigen presentation, enhancing suppressor T cells, reducing proinflammatory cytokines, and inhibiting lymphocyte trafficking into the central nervous system. Many clinical trials and over two decades of clinical experience have established it as a modestly efficacious and very safe therapeutic option for patients with relapsing MS. The side-effect profile includes flu-like symptoms, injection site reactions, liver function abnormalities, decreased peripheral blood counts, and worsening of depression. Its immunogenic properties and patients' genetic variability are associated with response heterogeneity.

KW - Disease-modifying therapy

KW - IFN

KW - Interferon beta

KW - Multiple sclerosis

UR - https://www.scopus.com/pages/publications/84987912497

U2 - 10.1016/B978-0-12-801914-6.00016-7

DO - 10.1016/B978-0-12-801914-6.00016-7

M3 - Chapter

AN - SCOPUS:84987912497

SN - 9780128019146

SP - 191

EP - 201

BT - Translational Neuroimmunology in Multiple Sclerosis

PB - Elsevier Inc.

ER -

Interferon β in Multiple Sclerosis: A Review

Abstract

Keywords

Access to Document

Fingerprint

Cite this